화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Journal of Industrial and Engineering Chemistry, Vol.62, 375-382, June, 2018
DOI10.1016/j.jiec.2018.01.017  Export Citation
Statistical optimization for production of mefenamic acid-nicotinamide cocrystals using gas anti-solvent (GAS) process
Napada Wichianphong1, 2, and Manop Charoenchaitrakool1, 2, †
  • 1Department of Chemical Engineering, Faculty of Engineering, Kasetsart University, Bangkok 10900, Thailand
  • 2Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University, Bangkok 10900, Thailand
E-mail:
This study aims to produce mefenamic acid.nicotinamide (MEF-NIC) cocrystal using gas anti-solvent (GAS) process in order to improve dissolution rate of MEF. Box.Behnken design was used to investigate the effects of three operating parameters: operating temperature, coformer-to-drug molar ratio and % drug saturation in the starting solution in the ranges of 25-45 °C, 3-5 and 70-90%, respectively. The analysis of experimental design showed that coformer-to-drug molar ratio and %drug saturation are significant parameters affecting the dissolution rate of the cocrystals. At a temperature of 45 °C, a coformer-to-drug ratio of 5 and a %drug saturation of 70% were found to be the optimal conditions for achieving the fastest dissolution time. Additionally, the sieved MEF-NIC cocrystal obtained from the optimal GAS conditions showed an enhanced dissolution rate 38 times greater than that of pure MEF and 1.6 times greater than cocrystal from a traditional slow evaporation method.
Keywords:Cocrystal;Mefenamic acid;Nicotinamide;GAS process;Box-Behnken
  1. Shewale S, Shete AS, Doijad RC, Kadam SS, Patil VA, Yadav AV, Indian J. Pharm. Sci., 77, 328 (2015)
  2. Tagalpallewar VR, Int. J. Pharm. Sci. Rev. Res., 43, 155 (2017)
  3. Kaur J, Aggarwal G, Singh G, Rana AC, Int. J. Pharm. Pharm. Sci., 4, 47 (2012)
  4. Babu VR, Areefulla SH, Mallikarjun V, J. Pharm. Res., 3, 141 (2010)
  5. Kanaujia P, Poovizhi P, Ng WK, Tan RBH, Powder Technol., 285, 2 (2015)
  6. Hart ML, Do DP, Ansari RA, Rizvi SAA, J. Dev. Drugs, 2, 1 (2013)
  7. Blagden N, de Matas M, Gavan PT, York P, Adv. Drug Deliv. Rev., 59, 617 (2007)
  8. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G, Int. J. Pharm., 419, 1 (2011)
  9. Kotak U, Prajapati V, Solanki H, Jani G, Jha P, World J. Pharm. Pharm. Sci., 4, 1484 (2015)
  10. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ, J. Pharm. Sci., 95, 499 (2006)
  11. Vaghela P, Tank HM, Jalpa P, Indo Am. J. Pharm. Res., 4, 5055 (2014)
  12. Ervasti T, Aaltonen J, Ketolainen J, Int. J. Pharm., 486, 121 (2015)
  13. Abramov YA, Loschen C, Klamt A, J. Pharm. Sci., 101, 3687 (2012)
  14. Neurohr C., Erriguible A., Laugier S., Subra-Paternault P., Chem. Eng. J., 303, 238 (2016)
  15. Imchalee R, Charoenchaitrakool M, J. Ind. Eng. Chem., 25, 12 (2015)
  16. Neurohr C, Revelli AL, Billot P, Marchivie M, Lecomte S, Laugier S, Massip S, Subra-Patemault P, J. Supercrit. Fluids, 83, 78 (2013)
  17. Ober CA, Gupta RB, AAPS PharmSciTech, 13, 1396 (2012)
  18. Ober CA, Montgomery SE, Gupta RB, Powder Technol., 236, 122 (2013)
  19. Padrela L, Rodrigues MA, Velaga SP, Matos HA, de Azevedo EG, Eur. J. Pharm. Sci., 38, 9 (2009)
  20. Kotbantao G, Charoenchaitrakool M, J. CO2 Util., 17, 213 (2017)
  21. Ahmed N, Mora-Huertas CE, Jaafar-Maalej C, Fessi H, Elaissari A, John Wiley & Sons, Ltd., United Kingdom, pp. 151 2013.
  22. Erriguible A, Neurohr C, Revelli AL, Laugier S, Fevotte G, Subra-Paternault P, J. Supercrit. Fluids, 98, 194 (2015)
  23. Rao KRSS, Nagabhushanam MV, Chowdary KPR, Indian J. Pharm. Sci., 73, 243 (2011)
  24. Fulop I, Gyeresi A, Kiss L, Deli MA, Croitoru MD, Szabo-Revesz P, Aigner Z, Acta Pharm., 65, 453 (2015)
  25. Dixit M, Kulkarni PK, Bio Phys., 39, 5026 (2011)
  26. Derle DV, Bele M, Kasliwal N, Asian J. Pharm., 2, 30 (2008)
  27. Charoenchaitrakool M, Suttikornchai S, Songjitsomboon T, Chiang Mai J. Sci., 40, 440 (2013)
  28. Fabian L, Hamill N, Eccles KS, Moynihan HA, Maguire AR, McCausland L, Lawrence SE, Cryst. Growth Des., 11, 3522 (2011)
  29. Utami D, Nugrahani I, Ibrahim S, Asian J. Pharm. Clin. Res., 10, 135 (2017)
  30. Lemmerer A, Esterhuysen C, Bernstein J, J. Pharm. Sci., 99, 4054 (2010)
  31. Ando S, Kikuchi J, Fujimura Y, Ida Y, Higashi K, Moribe K, Yamamoto K, J. Pharm. Sci., 101, 3214 (2012)
  32. Charoenchaitrakool M, Trisilanun W, Srinopakhun P, Korean J. Chem. Eng., 27(3), 950 (2010)
  33. Mudalip SKA, Abu Bakar MR, Jamal P, Adam F, J. Chem. Eng. Data, 58(12), 3447 (2013)
  34. Barrak N, Mannai R, Zaidi M, Kechida M, Helal AN, J. Geosci. Environ. Prod., 4, 50 (2016)
  35. Medina JR, Hernandez J, Hurtado M, Int. J. Appl. Pharm., 9, 54 (2017)
  36. Collier PS, in: Benet LZ, Levy G, Ferraiolo BL(Eds.), Pharmacokinetics, Plenum Press, New York, pp. 403 1984.
  37. Langenbucher F, in: Dressman J, Kramer J(Eds.), Pharmaceutical Dissolution Testing, Taylor & Francis Group, New York, pp. 251 2005.
  38. Mourabet M, El Rhilassi A, El Boujaady H, Bennani-Ziatni M, Taitai A, Arab. J. Chem., 10, S3292 (2017)
  39. Kirboga S, Oner M, Powder Technol., 249, 95 (2013)
  40. Cardot JM, Davit BM, AAPS J., 14, 491 (2012)
  41. Titapiwatanakun V, Basit AW, Gaisford S, Cryst. Growth Des., 16, 3307 (2016)
  42. Schultheiss N, Newman A, Cryst. Growth Des., 9, 2950 (2009)
  43. Haeria NA, Ismail I, Int. J. PharmTech Res., 8, 166 (2015)
  44. Joglekar AM, May AT, Cereal Foods World, 32, 857 (1987)
  45. Cui FJ, Li Y, Xu ZH, Xu HY, Sun K, Tao WY, Bioresour. Technol., 97(10), 1209 (2006)
  46. Zhang ZM, Zheng HL, J. Hazard. Mater., 172(2-3), 1388 (2009)
  47. Prawiro WS, Murtini G, Suprapti T, Cartika H, Asian J. Appl. Sci., 4, 899 (2016)
  48. Padrela L, Rodrigues MA, Tiago J, Velaga SP, Matos HA, de Azevedo EG, J. Supercrit. Fluids, 86, 129 (2014)